

Novartis / Novartis Pharmaceuticals Corporation


Novartis

Novartis

Novartis BRAF inhibitors including BRAF V600 inhibitors are used to treat patients with BRAF V600E mutations¹⁾
 Novartis MEK inhibitors including BRAF V600 inhibitors are used to treat patients with BRAF V600E mutations²⁾ who have not responded to MAPK
 inhibitors BRAF and MEK inhibitors³⁻⁵⁾

BRAF inhibitors **MEK** inhibitors

Image



1) Rheault TR, et al.: ACS Med Chem Lett 4(3) 358-62(2013)
 2) Gilmartin AG, et al.: Clin Cancer Res 17(5) 989-1000(2011)
 3) Flaherty KT, et al.: N Engl J Med 367(18) 1694-703(2012)
 4) Greger JG, et al.: Mol Cancer Ther 11(4) 909-20(2012)
 5) Long GV, et al.: Lancet 386(9992) 444-51(2015)

□□□□□□□□□□□□□□□□

□□□□□□